Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin Add-on to Propranolol for Portal Hypertension in Cirrhosis
NCT02508623Phase 3Unknown
- Sponsor
- Università di Padova
- Start
- Jul 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Portal Hypertension (PH) comparing Rifaximin + Propranolol with Placebo + Propranolol (2 arms). Primary endpoint: Change of Hepatic Venous Pressure Gradient at Day 60. Status: unknown.
02
Drugs
rifaximin
03
Conditions
Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT02508623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508623.